Literature DB >> 2177293

Autoinduction of rifabutin metabolism in man.

M Strolin Benedetti1, C Efthymiopoulos, D Sassella, E Moro, M Repetto.   

Abstract

1. The pharmacokinetics of the antimycobacterial agent rifabutin were studied in healthy volunteers, following single (450 mg) and repeated (450 mg once daily for 10 days) oral administration. 2. After repeated administration, induction of metabolism was indicated by lower AUC and Cmin values, compared to the corresponding theoretical values. The elimination half-life was unchanged after repeated administration. 3. Induction of presystemic extrahepatic metabolism, which seems to be important in the availability of rifabutin, should be mainly responsible for the decrease in the AUC observed, while induced systemic clearance (if any) should be of minor importance. 4. Induction of presystemic extrahepatic metabolism after repeated administration has also been reported for rifampicin, an antibiotic agent with hepatic enzyme-inducing properties, which has a structure similar to rifabutin but a different pharmacokinetic profile.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177293     DOI: 10.3109/00498259009046832

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  11 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex.

Authors:  R C Li; S Nightingale; R C Lewis; D C Colborn; P K Narang
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients.

Authors:  R C Li; P K Narang; J Sahai; W Cameron; J R Bianchine
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole.

Authors:  C B Trapnell; C Jamis-Dow; R W Klecker; J M Collins
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 6.  Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; A Fitton
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

Review 7.  Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Gilbert Deray
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 8.  Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.

Authors:  Jiezhong Chen; Kenneth Raymond
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-02-15       Impact factor: 3.944

Review 9.  Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.

Authors:  M Strolin Benedetti; P Dostert
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

10.  Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy.

Authors:  Junko Tanuma; Kazumi Sano; Katsuji Teruya; Koji Watanabe; Takahiro Aoki; Haruhito Honda; Hirohisa Yazaki; Kunihisa Tsukada; Hiroyuki Gatanaga; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.